Key clinical point: FMX101 4% topical minocycline foam is effective and safe for the treatment of moderate-to-severe acne vulgaris.
Major finding: In a phase 3 study, FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline and a greater rate of IGA treatment success vs foam vehicle group at week 12.
Study details: A 12-week, multicenter, randomized, double-blind, vehicle-controlled study. 1,488 participants were in the intent-to-treat population.
Raoof TJ, et al. J Am Acad Dermatol. 2019 June 1. doi: 10.1016/j.jaad.2019.05.078.